Zacks Research Has Pessimistic Outlook of CRSP Q1 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Zacks Research dropped their Q1 2025 earnings estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will post earnings of ($1.60) per share for the quarter, down from their previous estimate of ($1.51). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($1.65) EPS, Q3 2025 earnings at ($1.54) EPS, Q4 2025 earnings at ($1.60) EPS, FY2025 earnings at ($6.39) EPS, Q1 2026 earnings at ($1.82) EPS, Q2 2026 earnings at ($1.67) EPS, Q3 2026 earnings at ($1.35) EPS, Q4 2026 earnings at ($1.32) EPS and FY2026 earnings at ($6.16) EPS.

A number of other brokerages have also weighed in on CRSP. Barclays lowered their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Chardan Capital reissued a “buy” rating and set a $94.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Bank of America dropped their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, JMP Securities reiterated a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, December 20th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $77.59.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $39.41 on Monday. The stock has a 50-day moving average of $42.77 and a 200-day moving average of $46.53. CRISPR Therapeutics has a one year low of $36.52 and a one year high of $91.10. The company has a market cap of $3.36 billion, a PE ratio of -13.93 and a beta of 1.67.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Several large investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC raised its stake in CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after purchasing an additional 1,474,439 shares in the last quarter. Baker BROS. Advisors LP increased its holdings in shares of CRISPR Therapeutics by 743.1% in the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock worth $39,608,000 after buying an additional 743,075 shares during the last quarter. State Street Corp raised its position in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after buying an additional 599,304 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of CRISPR Therapeutics during the 4th quarter worth $3,231,000. Finally, Van ECK Associates Corp grew its position in CRISPR Therapeutics by 5,269.3% in the fourth quarter. Van ECK Associates Corp now owns 83,010 shares of the company’s stock worth $3,267,000 after acquiring an additional 81,464 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.